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Background: Deep sternal wound infection (DSWI) is a severe complication after cardiac surgery, mostly caused
by staphylococci. Little is known about the optimal antibiotic management.
Methods: A 10 year retrospective analysis of 100 patients with staphylococcal DSWI after cardiac surgery in a
tertiary hospital. Treatment failure was defined as sternal wound dehiscence or fistula at the end of the pre-
scribed antibiotic therapy, 12 months later, or DSWI-related death.
Results: Most patients were male (83%) and the median age was 72 years [interquartile range (IQR) 63–76].
Coronary artery bypass was the most frequent preceding procedure (93%). The median time to diagnosis of
DSWI was 13 days (IQR 10–18) after surgery. Clinical presentation consisted of wound discharge in 77% of
patients. Coagulase-negative staphylococci were isolated in 54 and Staphylococcus aureus in 46 patients. All
patients received antibiotics and 95% underwent surgical debridement. The median duration of antibiotic
treatment was 47 days (IQR 41–78). During follow-up, 21 out of 100 patients experienced treatment failure.
Of these, 8/21 patients (38%) died from DSWI after a median of 12 days (IQR 8–30). In the multivariate analy-
sis, a rifampicin-containing antibiotic regimen was the only factor associated with lower risk of treatment
failure (hazard ratio 0.26, 95% confidence interval 0.10–0.64, P¼0.004). Prolonged treatment (12 weeks
instead of 6 weeks) did not alter outcome (P¼0.716) in patients without prosthetic valve endocarditis.
Conclusions: Treatment of rifampicin-susceptible staphylococcal DSWI with a rifampicin-containing antibiotic
regimen may improve the outcome. After surgical debridement an antibiotic treatment of 6 weeks may be ade-
quate for staphylococcal DSWI.
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Introduction
Deep sternal wound infection (DSWI) is an infrequent but severe
complication after cardiac surgery with reported incidence rates
between 1% and 2%,1 – 4 and mortality rates between 10% and
20%.1,3,5,6 In addition, DSWI is associated with a prolonged hos-
pital stay, repeated surgical procedures and increased costs.7,8
Known risk factors of DSWI are male gender, advanced age
and co-morbidities such as obesity, diabetes mellitus, chronic
obstructive pulmonary disease, heart failure and renal
failure.1,7,8 Among surgical procedures, the use of both internal
mammary arteries, longer duration of operation, extensive
bleeding, prolonged mechanical ventilation and the need for
intra-aortic balloon pump support post-operatively have also
been associated with an increased risk of DSWI.1,7 – 10 Clinical
manifestation of DSWI is variable. Wound discharge, pain, ten-
derness and sternal instability are the most common local
signs, whereas fever, sepsis and elevation of inflammatory par-
ameters are less frequently reported.5 The most common causa-
tive microorganisms are coagulase-negative staphylococci
(CoNS) and Staphylococcus aureus, followed by Gram-negative
bacteria and fungi.3,7,11 – 13 Moreover, nasal carriers of S. aureus
are at increased risk for DSWI.14
Generally, treatment of DSWI requires aggressive surgical
debridement and parenteral antibiotics.3,7,11 – 13 Various surgical
treatment modalities have been established for the treatment
of DSWI. Debridement with secondary refixation of the
sternum and continuous antibiotic irrigation was the standard
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procedure for years. More recently, advances in surgical tech-
niques including primary sternum preservation, sternectomy
combined with reconstruction by vascularized soft tissue flaps
such as greater omentum or pectoral muscle, and
vacuum-assisted closure systems15,16 have led to an improved
survival.3,17,18 Empirical antibiotic treatment should be directed
at staphylococci, the most frequently isolated microorganisms,
and streamlined as results of blood cultures and deep sternal
wound drainage become available.3,7,12,13,19 The duration of
antibiotic therapy is quite variable in the literature, ranging
from a few weeks to months, depending on the severity of infec-
tion and the presence of mediastinitis, osteomyelitis or endocar-
ditis.20,21 However, very few data exist on the optimal antibiotic
regimen and duration of therapy.
The aim of this study was to investigate risk factors associ-
ated with treatment failure in patients with staphylococcal
DSWI after cardiac surgery and to evaluate the optimal antibiotic
management of DSWI.
Methods
Study population and design
This study is a 10 year retrospective analysis of all patients diagnosed
with staphylococcal DSWI after cardiac surgery by median sternotomy
at the University Hospital Basel, Switzerland, between 1998 and 2008.
The University Hospital Basel is a tertiary care centre performing 600
cardiovascular surgical interventions yearly.
Data collected from chart review included demographic characteristics,
date of hospitalization, co-morbidities (cardiovascular disease, diabetes
mellitus, chronic obstructive lung disease, heart and renal failure), peri-
operative risk [European System for Cardiac Operative Risk Evaluation
(EuroSCORE) and American Society of Anesthesiologists (ASA) classifi-
cation], antibiotic prophylaxis, type and duration of cardiac surgery and
early post-operative complications (bleeding, prolonged mechanical venti-
lation, cardiopulmonary resuscitation). Blood tests included creatinine,
glucose, white blood cell count, C-reactive protein and haemoglobin.
Further collected data comprised the clinical presentation of DSWI
(wound erythema, discharge, sternal instability), the presence of endocar-
ditis, mediastinitis and microbiological tests (superficial swabs, deep
swabs, sternal biopsies, blood cultures), antibiotic treatment and surgical
procedures.
DSWI was defined according to the criteria for deep surgical site infec-
tion of the CDC,22 i.e. at least one of the following criteria was required:
(i) a microorganism was isolated from culture of mediastinal tissue or
fluid; evidence of mediastinitis was seen during operation; or one of
the following: (ii) chest pain, sternal instability or fever with either puru-
lent discharge from the mediastinum or a microorganism was isolated
from blood culture or culture of drainage of the mediastinal area.
DSWI was categorized as osteomyelitis when infection was limited to
the sternal bone, and as mediastinitis when infection included the med-
iastinal area, according to the intraoperative report.
Endocarditis was defined by the modified Duke criteria23 for diagnosis
of infective endocarditis. Microbiological susceptibility tests were per-
formed according to CLSI guidelines.
This study was approved by the local Ethics Committee (EKBB #55/08).
Treatment of DSWI
As the prevalence of methicillin-resistant S. aureus (MRSA) is very low in
our institution (,5% among S. aureus), empirical treatment of DSWI
consisted of amoxicillin/clavulanate or flucloxacillin given intravenously,
and piperacillin/tazobactam, carbapenems or cefepime if infection due
to Gram-negative bacteria was suspected. The appropriateness of the
prescribed therapy was evaluated according to written internal guidelines
of the infectious diseases division, which are closely adapted from inter-
national guidelines for the treatment of endocarditis and osteomyel-
itis.23 – 28 In patients without endocarditis, switch to an oral regimen
consisting of a fluoroquinolone combined with rifampicin, fusidic acid
combined with rifampicin or clindamycin alone was generally rec-
ommended after a 2 week course of intravenous antibiotic treatment.
The overall duration of antibiotic therapy was 6 weeks, or 12 weeks if
sternal wires were not removed, in analogy to treatment of osteomyelitis
associated with a foreign body.21,27
Outcome measures
Treatment failure was defined as the presence of wound dehiscence,
fistula, DSWI-related re-hospitalization or DSWI-related death. The
outcome was evaluated after completing the prescribed antibiotic
therapy, i.e. after 6 or 12 weeks, and 12 months later by in-hospital
data and a questionnaire sent to the treating physicians.
Statistical analysis
Basic demographic characteristics, co-morbidities, laboratory parameters,
surgical management and antibiotic therapy were compared according to
the occurrence of treatment failure in the first year after diagnosis of DSWI,
using the x2 test or Fisher’s exact test for categorical variables and the
Mann–Whitney test for continuous variables. Kaplan–Meier curves were
used to describe cumulative incidence of treatment failure according to
antibiotic regimens used. Cox hazard proportional models were used to
estimate the hazard ratios (HRs) of treatment failure during the first year
after diagnosis of DSWI. All patients were censored at 1 year after diagnosis
of DSWI if no treatment failure or death had occurred.
All analyses were performed using STATATM software version 9.2 for
Windows (StataCorp, College Station, TX, USA).
Results
Study population
Among 5440 patients who underwent cardiac surgery between
January 1998 and March 2008 at the University Hospital Basel,
we identified 120 patients with DSWI. Of those, 20 subjects did
not meet the case definition and were excluded because Entero-
bacteriaceae (n¼13), enterococci spp. (n¼3) or no microorgan-
ism (n¼4) were isolated. The final analysis was performed on
100 patients with DSWI caused by staphylococci, i.e. CoNS in
54 and S. aureus in 46 patients. The median age was 72 years
[interquartile range (IQR) 63–76] and most patients were male
(83%). Coronary artery bypass with or without valve replacement
was the most frequent preceding procedure (93%). Baseline
characteristics according to the outcome at 12 months after
diagnosis of DSWI are shown in Table 1. Demographic character-
istics, type of cardiac surgery, perioperative risk according to
EuroSCORE, ASA classification and co-morbidities were similar
in patients who experienced treatment failure compared with
those who were cured at 12 months after DSWI.
Clinical presentation and microbiological findings
of DSWI
DSWI was diagnosed at a median of 13 days (IQR 10–18) after
primary cardiac surgery. The clinical presentation consisted of
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wound discharge in 77%, fever in 52%, local erythema in 49%
and sternal instability in 47% of patients. Systemic inflammatory
parameters were elevated in 95% of patients with a median
white blood cell count of 12.6×109/L (IQR 8.9–18.1) and
C-reactive protein of 170 mg/L (IQR 101–267). Mediastinitis
was noted in one-third of patients and endocarditis in nine
patients; of those, seven had prosthetic valve endocarditis.
Among 46 isolates of S. aureus, 3 (7%) were methicillin resistant
(MRSA), 3 (7%) were resistant to ciprofloxacin, 4 (9%) were resist-
ant to clindamycin, but none was resistant to rifampicin. In con-
trast, among 54 CoNS isolates, 39 (72%) showed resistance to
oxacillin, 26 (48%) to ciprofloxacin, 8 (15%) to clindamycin and
5 (9%) to rifampicin.
The clinical presentation, laboratory and microbiological find-
ings were similar in patients who experienced treatment failure
and in those who were cured at 12 months after diagnosis of
Table 1. Baseline characteristics of 100 patients with staphylococcal deep sternal wound infection after cardiac surgery according to the outcome
at 1 year
Characteristic
Treatment failure, N¼21 Treatment success, N¼79
P valuena %a na %a
Median age, years (IQR) 71 63–75 73 63–77 0.621
Male gender 17 81 68 86 0.559
Median body mass index, kg/m2 (IQR) 27 26–30 28 25–32 0.532
Median EuroSCORE classification (IQR) 4 2–5 4 2–6 0.781
ASA classification IV 2 10 17 22 0.420
Co-morbidity 17 81 62 78 0.805
Diabetes mellitus 8 38 26 33 0.656
Heart failure (NYHA III–IV) 10 48 49 62 0.233
Chronic obstructive lung disease 5 24 27 34 0.365
Current smoker 12 57 53 67 0.396
Cardiac surgery
CABG only 17 81 45 57 0.453
CABG and valve replacement 2 10 29 37
other 2 10 5 6
Median duration of cardiac surgery, min (IQR) 225 185–278 220 180–265 0.539
Perioperative complicationsb 3 14 10 13 0.844
Fever (temperature .38.58C) 12 57 40 51 0.596
Local signs
erythema 12 57 37 47 0.401
wound discharge 19 90 58 73 0.102
sternal instability 9 43 38 48 0.669
Median white cell count (IQR) 13.9 8.9–20.3 12.4 8.9–17.2 0.669
Median C-reactive protein, mg/L (IQR) 195 123–307 163 97–266 0.224
Microorganism
S. aureus 12 57 32 41 0.239
CoNS 9 43 47 59
Mediastinitis 11 52 21 27 0.024
Endocarditis 0 — 9 11 0.108
NYHA, New York Heart Association; CABG, coronary artery bypass graft; CoNS, coagulase-negative staphylococci. Statistically significant values are
shown in bold.
aUnless otherwise stated.
bBleeding in six patients, prolonged mechanical ventilation in six patients and cardiopulmonary resuscitation in one patient.
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DSWI (Table 1). Individuals with DSWI complicated by mediasti-
nitis were more likely to experience treatment failure compared
with those without mediastinitis (52% versus 27%, P¼0.024).
The most common microbiological specimens taken were
deep swabs (84%), followed by superficial swabs (63%) and
sternal biopsies (43%). Blood cultures were drawn in 73% of
patients after a median of 11 days (IQR 8–15) post-operatively,
yielding S. aureus in 35 (48%) of these. Among diagnostic
tools, the causative microorganism of DSWI was identified in
86% of superficial swabs, in 94% of deep swabs and in 88% of
sternal biopsies performed before empirical antibiotic treatment
was started. In 60 patients with results of both superficial and
deep swabs available, agreement between both diagnostic
tools was observed in 77% of patients with S. aureus and in
68% of those with CoNS.
Management of DSWI
All patients with DSWI were treated with antibiotics according to
our internal guidelines and 95% of these were in addition to surgi-
cal debridement (Table 2). Overall, empirical antibiotic treatment
was started at a median of 12 days (IQR 10–17) after primary
cardiac surgery, and consisted of amoxicillin/clavulanate in 51%
of individuals, vancomycin in 20% and flucloxacillin in 13%.
According to the definitive microbiological results, the empirical
initial antibiotic regimen was retrospectively considered to be
appropriate in 73% of patients. Overall, 87% of individuals
switched from an intravenous to an oral regimen after a median
time of 19 days (IQR 12–31). Oral antibiotic treatment consisted
of fluoroquinolones in combination with rifampicin in 45%,
fusidic acid in combination with rifampicin in 14% and clindamycin
alone in 11% of patients. Rifampicin was added to the antibiotic
regimen in 76% of patients at a median of 8 days (IQR 3–15)
after empirical antibiotic therapy, and continued for a median of
42 days (IQR 28–70). Patients who received a combination anti-
biotic treatment containing rifampicin were less likely to experi-
ence treatment failure compared with those who did not receive
rifampicin (P¼0.024). The overall median duration of antibiotic
treatment was 47 days (IQR 41–78). Surgical debridement was
performed in 95% of patients at a median of 14 days (IQR 10–
20) after primary cardiac surgery. Repeated debridements were
necessary in 42% of patients, and removal of sternal wires in 7%
of individuals. Adjuvant surgical techniques comprised irrigation/
suction systems in 32% of patients, greater omentum or pectoral
muscle flap reconstruction in 23% and vacuum-assisted systems
in 14%. Of note, adjuvant surgical procedures varied over the study
period, the irrigation/suction system being predominantly used
before 2004 and vacuum-assisted closure dressings thereafter.
No differences in outcome were noted among different adjuvant
surgical procedures.
Table 2. Antibiotic treatment and surgical management of 100 patients with staphylococcal deep sternal wound infection after cardiac surgery
according to the outcome at 1 year
Characteristic
Treatment failure, N¼21 Treatment success, N¼79
P valuena %a na %a
Debridement 20 95 75 95 0.718
Adequate empirical antibiotic therapy 16 76 57 72 0.476
Empirical therapy
amoxicillin/clavulanate 14 67 37 47 0.123
flucloxacillin 0 — 13 16
vancomycin 5 24 15 19
other 2 10 14 18
Oral regimen
ciprofloxacin 7 33 46 58 0.387
fusidic acid 2 10 7 9
clindamycin 2 10 8 10
other 10 48 18 23
Antibiotic regimen containing rifampicin 12 57 64 81 0.023
Median duration of intravenous antibiotic therapy, days (IQR) 16 11–27 18 14–29 0.213
Median duration of antibiotic therapy, days (IQR) 36 13–47 51 43–84 <0.001
Local therapy
vacuum-assisted closure 3 14 11 14 0.603
irrigation/suction drainage 7 33 25 32 0.883
plastic surgery 6 29 17 22 0.339
Statistically significant values are shown in bold.
aUnless otherwise stated.
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Outcome of DSWI
A complete follow-up was available for all 100 patients, with
information either after 12 months in 85 patients or beforehand
in 15 patients who died. Overall, 21 out of 100 individuals experi-
enced a treatment failure during the first year after diagnosis of
DSWI, half of these within the first month of treatment. Thirteen
patients required re-hospitalization due to DSWI. Among 15 indi-
viduals who died, 8 deaths were attributed to DSWI, occurring at
a median of 12 days (IQR 8–30) after diagnosis of DSWI. The
overall median hospital stay amounted to 32 days (IQR 21–46).
In the univariate analysis, DSWI with mediastinitis was a risk
factor of treatment failure [HR 2.75, 95% confidence interval (CI)
1.17–6.50, P¼0.020], whereas a rifampicin-containing antibiotic
regimen was associated with a lower probability of treatment
failure (HR 0.36, 95% CI 0.15–0.86, P¼0.021).
In the multivariate analysis, after adjustment for age, anti-
biotic treatment, microorganism, presence of mediastinitis and
adjuvant surgical procedure, a rifampicin-containing antibiotic
regimen was the only factor associated with lower risk of treat-
ment failure (HR 0.26, 95% CI 0.10–0.64, P¼0.004) (Table 3
and Figure 1).
In a subgroup analysis of 85 patients receiving antibiotic
treatment for at least 4 weeks, no differences in outcome were
observed between a treatment duration of 6 and 12 weeks
(P¼0.716). In these patients, baseline demographic character-
istics, clinical presentation including endocarditis and mediastini-
tis, causative microorganism and adjuvant local surgical
therapies were similar in patients treated for 6 and 12 weeks.
Discussion
In our study, involving 100 individuals who developed staphylo-
coccal DSWI following cardiac surgery in a tertiary hospital, a
rifampicin-containing antibiotic regimen significantly improved
outcome of DSWI, even after a long follow-up of at least 1 year.
Treatment of DSWI requires surgical debridement and parent-
eral antibiotics.3,7,11 – 13 However, data on the optimal antibiotic
management of DSWI are scarce; in particular the duration of
therapy is quite variable, and no data on the use of rifampicin
in DSWI have been reported in the literature so far. Combination
antibiotic therapy with rifampicin and fluoroquinolones has been
shown to be equally effective as standard treatment with intra-
venous flucloxacillin for the treatment of severe staphylococcal
infections and right-side endocarditis.29,30 Furthermore, higher
cure rates of foreign body infections were reported in patients
treated with fluoroquinolones or fusidic acid when given in com-
bination with rifampicin,21,31 – 33 possibly related to its activity
against bacteria embedded in biofilms.34 In our institution, the
overall prevalence of MRSA is low (,5%). Therefore, empirical
treatment of DSWI consisted most commonly of intravenous
amoxicillin/clavulanate or flucloxacillin, considered to be appro-
priate in most patients. In our study population, all S. aureus iso-
lates and 90% of CoNS strains were susceptible to rifampicin.
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Figure 1. Probability of treatment failure within the first year according to antibiotic regimen in 100 patients with staphylococcal deep sternal wound
infection.
Table 3. Risk factors [hazard ratio (HR)] of treatment failure during the
first year of therapy in 100 patients with staphylococcal deep sternal
wound infection, multivariate analysis
Characteristic HRa 95% CI P value
Age, per 10 years older 0.97 0.62–1.50 0.862
Co-morbidity 1.01 0.33–3.11 0.980
CoNS versus S. aureus 0.51 0.19–1.38 0.186
Mediastinitis 2.10 0.79–5.58 0.135
Antibiotic regimen containing rifampicin 0.26 0.10–0.64 0.004
Adjuvant surgical treatment 1.47 0.57–3.81 0.428
Statistically significant values are shown in bold.
aAdjusted for all variables listed in the table.
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Sternal wire, the most common procedure for sternum closure, is
considered to be an implant. Therefore, it is not surprising that
rifampicin has outstanding activity against implant-associated
infections.33,35 Importantly, during the entire study period, rifam-
picin was never used as a single drug, and emergence of resist-
ance to rifampicin was not observed. An antibiotic regimen
containing rifampicin was generally very well tolerated, and no
patient required antibiotic treatment to be stopped because of
adverse events.
The overall treatment failure rate of 21% and a mortality of
8% during the first year after diagnosis of DSWI are consistent
with those reported in case series, where treatment failure
rates of 15%–35%3,6 and mortality rates of 6%–20%1,3,5,6
were related to different surgical procedures, older age and
co-morbidities.36 – 41 Similarly, we noted a trend towards higher
mortality among patients with co-morbidities. Moreover, the
presence of mediastinitis was associated with higher risk of
treatment failure, and patients with DSWI due to S. aureus
showed higher mortality rates compared with those with
CoNS-related DSWI regardless of endocarditis (data not
shown). This is in agreement with previous studies, where
CoNS-related infections were associated with mild local wound
alterations and better outcome compared with S. aureus
causing sepsis and higher mortality.5,42 Recently, the use of a
vacuum-assisted closure system was shown to improve survival
and accelerate healing of DSWI.36,39,40,43 However, we could not
detect any significant differences in outcome depending on the
adjuvant surgical procedure, possibly due to the low number of
patients treated with different procedures.
In our study, no differences in outcome were observed
between patients treated for 6 weeks compared with 12 weeks
for DSWI not complicated by prosthetic valve endocarditis. In
analogy to guidelines for osteomyelitis treatment,21 after com-
pletion of a 2 week intravenous antibiotic course, patients
without endocarditis were switched to an oral regimen for an
additional 4–10 weeks. The intravenous and overall treatment
duration was quite variable, generally longer in patients with
endocarditis and in those treated with adjuvant surgical pro-
cedures, reflecting more extended infection. Nevertheless,
there was no difference in outcome between a 6 week and
12 week antibiotic course in patients treated for at least
4 weeks and without prosthetic valve endocarditis, as only
three failures occurred after 2 months of treatment and no
relapses were observed after completion of the prescribed treat-
ment. The present data suggest that a 2–3 week course of intra-
venous antibiotic therapy followed by a 4 week oral antibiotic
regimen, mostly as a combination of fluoroquinolones and rifam-
picin, is adequate for staphylococcal DSWI, provided that endo-
carditis has been excluded. Increasing concern over the
emergence of resistance to fluoroquinolones in clinical practice
emphasizes the need for randomized studies evaluating new
drugs such as daptomycin and linezolid as monotherapy or in
combination with rifampicin.
Strengths and limitations
This study has several strengths. First, it includes all patients with
staphylococcal DSWI diagnosed at our hospital during a 10 year
period with exact information on 1 year outcome and the com-
plete follow-up for all patients. Also, this is, to our knowledge, the
largest case series with detailed information on antibiotic treat-
ment for DSWI reported to date. In particular, this is the first
study analysing a rifampicin-containing antibiotic treatment of
DSWI. Importantly, the results apply to a large number of
patients with DSWI, as staphylococci are the most frequent
pathogens isolated. We acknowledge some limitations. The ret-
rospective design and the heterogeneity of adjuvant surgical pro-
cedures did not allow us to draw conclusions on the optimal
adjuvant surgical management of these patients, although this
was not within the scope of this study. On the other hand, the
antibiotic regimen was quite consistent over the 10 years as
the staff physicians basically remained unchanged. Importantly,
we cannot exclude a selection bias of patients who received a
longer antibiotic treatment, i.e. we cannot rule out that
outcome in this specific patient group would have been different
if treatment was only for 6 weeks. However, significant differ-
ences in baseline characteristics of patients treated for 6 weeks
versus longer were not observed. MRSA infections were uncom-
mon in our study. Resistance to methicillin frequently co-occurs
with rifampicin resistance, rendering our treatment option
futile. If susceptible to rifampicin, patients should be advised
never to take rifampicin alone, but always in combination with
other antibiotics. In addition, our local policy—based on expert
opinion—recommends using rifampicin only when the wound
has been closed. An open wound might increase the risk of
rifampicin resistance despite combination therapy.
In conclusion, our study indicates that treatment of staphylo-
coccal DSWI with a rifampicin-containing antibiotic regimen
improves the outcome, provided the strain is susceptible to
rifampicin. Moreover, after surgical debridement, a 6 week anti-
biotic course may be adequate for DSWI, as the outcome was
similar in patients treated for 6 weeks compared with those
treated for 12 weeks. The results of our study should be con-
firmed by a randomized controlled trial.
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